On Thursday, Marsh & McLennan Companies, Inc. (NYSE:MMC)’s shares declined -0.27% to $52.08.
Marsh & McLennan Companies, Inc. (MMC), a global professional services firm offering clients advice and solutions in risk, strategy and people, recently declared the appointment of Mark McGivney as Chief Financial Officer, effective January 1, 2016. Mr. McGivney will report to Marsh & McLennan Companies’ President & CEO Dan Glaser and join the Company’s Executive Committee.
In this role, Mr. McGivney succeeds J. Michael Bischoff, who is retiring after having served as Chief Financial Officer since September 2012. Mr. Bischoff joined the Company in 1982 and held a number of senior financial administration positions before being named interim CFO in March 2012. Mr. Bischoff is predictable to serve as a part-time Senior Advisor to the Company through the first quarter of 2016.
Marsh & McLennan Companies, Inc., a professional services firm, provides advice and solutions primarily in the areas of risk, strategy, and people worldwide. It operates in two segments, Risk and Insurance Services; and Consulting.
Sanofi SA (ADR) (NYSE:SNY)’s shares gained 0.18% to $47.56.
Genzyme, a Sanofi company, declared that new investigational data on its marketed treatments, Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab), in addition to data from the company’s MS pipeline, will be presented during the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The meeting, to be held in Barcelona, Spain, October 7-10th, will feature more than 50 platform and poster presentations of investigational data from across Genzyme’s MS franchise.
In addition to its marketed therapies, Genzyme has an MS R&D pipeline seeking to address unmet needs for relapsing and progressive forms of MS through research in selective immunomodulation, neuroprotection and remyelination.
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
At the end of Thursday’s trade, UDR, Inc. (NYSE:UDR)‘s shares surged 0.58% to $34.68.
UDR, Inc. (NYSE: UDR), a leading multifamily real estate investment trust, declared that its Board of Directors declared a regular quarterly dividend on its common stock for the third quarter of 2015 in the amount of $0.2775 per share, payable in cash, on November 2, 2015 to UDR common stock shareholders of record as of October 12, 2015. The November 2nd dividend will be the 172nd successive quarterly dividend paid by the Company on its common stock.
UDR, Inc. is an independent real estate investment trust. The firm invests in the real estate markets of the United States. It owns, operates, acquires, renovates, develops, redevelops, and manages multifamily apartment communities.
Akorn, Inc. (NASDAQ:AKRX), ended its Thursday’s trading session with -1.00% loss, and closed at $28.22.
Akorn, Inc. (AKRX), a leading specialty pharmaceutical company, declared that it has launched Doxercalciferol Injection Solution, 4 mcg/2 mL in 2mL single-use vials. The launch follows an approval of an abbreviated new drug application for the product from the U.S. Food and Drug Administration on May 7, 2015. Akorn’s product is therapeutically equivalent to Hectorol(R) injection, marketed by Genzyme Corporation.
Akorn, Inc. develops, manufactures, and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter (OTC) consumer health products in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
